Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in Relapsed/Refractory Ovarian Cancer
NCT00445549Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vandetanib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoint: Number of Participants With Clinical Efficacy (CR, PR, or SD) at 24 weeks. Started Jan 2007; status: terminated.
02
Drugs
vandetanib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00445549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00445549.